600771.SH
广誉远
SSE · Healthcare · Drug Manufacturers - General · CN
CNY 13.24
−1.49%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.4B | 1.4B | 1.2B | 1.3B | 1.1B |
| Cost of Revenue | 464.1M | 443.7M | 322.2M | 347.4M | 367.2M |
| Gross Profit | 976.3M | 925.6M | 899.2M | 936.6M | 763.5M |
| Operating Expenses | |||||
| R&D Expense | 36.2M | 38.5M | 38.6M | 31.4M | 29.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 94.1M | 90.8M | 86.5M | 92.8M | 89.3M |
| Selling & Marketing Expense | 676.9M | 638.4M | 579.3M | 643.5M | 792.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 844.4M | 801.8M | 738.2M | 814.9M | 956.8M |
| Cost and Expenses | 1.3B | 1.2B | 1.1B | 1.2B | 1.3B |
| Operating Income (EBIT) | 118.9M | 110.1M | 90.8M | 114.8M | (273.4M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 111.9M | 103.0M | 80.8M | 100.4M | (265.1M) |
| Income Tax Expense | 44.3M | 39.3M | (2.8M) | 7.5M | (2.1M) |
| Bottom Line | |||||
| Net Income | 66.2M | 63.0M | 74.5M | 90.1M | (250.0M) |
| Earnings from Cont. Ops | 67.5M | 63.7M | 83.6M | 92.9M | (263.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 66.2M | 63.0M | 74.5M | 90.1M | (250.0M) |
| Per Share | |||||
| Basic EPS | CN¥0.14 | CN¥0.13 | CN¥0.15 | CN¥0.18 | (CN¥0.51) |
| Diluted EPS | CN¥0.14 | CN¥0.13 | CN¥0.15 | CN¥0.18 | (CN¥0.51) |
| Revenue Per Share | CN¥2.94 | CN¥2.82 | CN¥2.46 | CN¥2.57 | CN¥2.31 |
| Shares | |||||
| Basic Shares Outstanding | 489.6M | 485.0M | 496.4M | 500.4M | 490.2M |
| Diluted Shares Outstanding | 489.6M | 485.0M | 496.4M | 500.4M | 490.2M |
| Profitability Metrics | |||||
| EBITDA | — | 149.9M | 136.6M | 156.6M | (231.6M) |
| D&A | — | 39.7M | 45.8M | 41.8M | 41.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026